Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin

[1]  G. Bianchi,et al.  Effects of salmon calcitonin on the bone loss induced by ovariectomy , 1990, Calcified Tissue International.

[2]  J. Pouilles,et al.  The effects of menopause on longitudinal bone loss from the spine , 1993, Calcified Tissue International.

[3]  H. Rico,et al.  Total and regional bone mineral content in women treated with GnRH agonists , 1993, Calcified Tissue International.

[4]  R. Gleason,et al.  A Prospective, Randomized Trial of Gonadotropin-Releasing Hormone Agonist Plus Estrogen-Progestin or Progestin “Add-Back” Regimens for Women With Leiomyomata Uteri , 1994 .

[5]  R. Gleason,et al.  A Prospective, Randomized Trial of Gonadotropin‐Releasing Hormone Agonist Plus Estrogen‐Progestin or Progestin “Add‐Back” Regimens for Women With Leiomyomata Uteri , 1993, The Journal of clinical endocrinology and metabolism.

[6]  A. Friedman,et al.  Adverse effects of leuprolide acetate depot treatment. , 1993, Fertility and sterility.

[7]  M. Dawood,et al.  Impact of medical treatment of endometriosis on bone mass. , 1993, American journal of obstetrics and gynecology.

[8]  B. Riggs,et al.  Preventive effects of transdermal 17 beta-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. , 1993, American journal of obstetrics and gynecology.

[9]  R. Shaw.  Treatment of endometriosis , 1992, The Lancet.

[10]  M. A. Hansen,et al.  Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. , 1992, BMJ.

[11]  H. Judd,et al.  Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. , 1992, The Journal of clinical endocrinology and metabolism.

[12]  W. Horbert,et al.  Effects of phorbol myristate acetate on rat and chick osteoclasts , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  J. Conill,et al.  Higher incidence of carpal tunnel syndrome in oophorectomized women. , 1991, British journal of rheumatology.

[14]  J. Kanis,et al.  The use of nasal calcitonin in the treatment of post-traumatic algodystrophy. , 1991, British journal of rheumatology.

[15]  T. Spector,et al.  Oestrogens, joint disease, and cartilage. , 1991, Annals of the rheumatic diseases.

[16]  C. Snow-harter,et al.  Bone mineral density of the lumbar spine in endometriosis subjects compared to an age-similar control population. , 1991, The Journal of clinical endocrinology and metabolism.

[17]  R. Whitehouse,et al.  THE EFFECTS OF NAFARELIN AND DANAZOL ON VERTEBRAL TRABECULAR BONE MASS IN PATIENTS WITH ENDOMETRIOSIS , 1990, Clinical endocrinology.

[18]  R. Ziegler,et al.  Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3. , 1990, The Journal of clinical endocrinology and metabolism.

[19]  C. Christiansen,et al.  Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? , 1990, The Journal of clinical endocrinology and metabolism.

[20]  A. Decherney,et al.  Reduced bone mass in reproductive-aged women with endometriosis. , 1989, The Journal of clinical endocrinology and metabolism.

[21]  L. De Cecco,et al.  Effects of gonadotrophin-releasing hormone agonist on uterine fibroids and bone density. , 1989, Maturitas.

[22]  V. Lewis,et al.  Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol. , 1989, Fertility and sterility.

[23]  C. Christiansen,et al.  The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. , 1988, The Journal of clinical endocrinology and metabolism.

[24]  R. Hesp,et al.  REVERSIBLE TRABECULAR BONE DENSITY LOSS FOLLOWING INDUCED HYPO‐OESTROGENISM WITH THE GnRH ANALOGUE BUSERELIN IN PREMENOPAUSAL WOMEN , 1988, Clinical endocrinology.

[25]  J. Reginster,et al.  One year's treatment of paget's disease of bone by synthetic salmon calcitonin as a nasal spray , 1988, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  J. Reginster,et al.  1-YEAR CONTROLLED RANDOMISED TRIAL OF PREVENTION OF EARLY POSTMENOPAUSAL BONE LOSS BY INTRANASAL CALCITONIN , 1987, The Lancet.

[27]  S. Ljunghall,et al.  Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition. , 1987, The Journal of clinical endocrinology and metabolism.

[28]  J. Reginster,et al.  Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. , 1985, Clinical and experimental rheumatology.

[29]  J. Sandow,et al.  CLINICAL APPLICATIONS OF LHRH AND ITS ANALOGUES , 1983, Clinical endocrinology.